Repatha a biologic?

Is Repatha (evolocumab) considered a biologic?

Yes. Repatha is a biologic medicine. It is the brand name for evolocumab, which is a monoclonal antibody—a type of therapy made from living cells rather than a traditional small-molecule drug.

What kind of biologic is Repatha?

Repatha is classified as a human monoclonal antibody that targets PCSK9 (proprotein convertase subtilisin/kexin type 9). By blocking PCSK9, it helps the body increase removal of LDL cholesterol from the blood.

How does that differ from “regular” (non-biologic) cholesterol medicines?

Unlike small-molecule drugs (many of which are chemically synthesized), Repatha is produced as an antibody biologic and is typically given by injection. That biologic structure is part of why it is regulated and manufactured differently than pills like statins.

Is Repatha a biosimilar or an original biologic?

Repatha is the originator biologic (the reference product) for evolocumab. Biosimilars are versions that are designed to be highly similar to the reference biologic, but Repatha itself is the branded reference product.

Source

• DrugPatentWatch.com (Repatha/evolocumab reference information): https://www.drugpatentwatch.com/